Finance

Lists
Why is RPGLIFE down 2,19%?
Dive Deeper
RPGLIFE:NSE
RPG Life Sciences Ltd
2 549,00 INR
-2,19%
(-57,10) 1D
20-ноя., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for RPGLIFE...
Open
2 600,00 INR
High
2 615,90 INR
Low
2 506,00 INR
Mkt. cap
42,16 млд
Avg. vol.
21,70 миң
Volume
5,99 миң
Dividend
0,94%
Quarterly dividend
6,00 INR
Ex-dividend date
2026-ж., 9-июл.
P/E ratio
37,97
52-wk high
3 127,80 INR
52-wk low
1 733,00 INR
EPS
67,13 INR
Shares outstanding
16,54 млн
No. of employees
1 миң
Open
2 600,00 INR
High
2 615,90 INR
Low
2 506,00 INR
Mkt. cap
42,16 млд
Avg. vol.
21,70 миң
Volume
5,99 миң
Dividend
0,94%
Quarterly dividend
6,00 INR
Ex-dividend date
2026-ж., 9-июл.
P/E ratio
37,97
52-wk high
3 127,80 INR
52-wk low
1 733,00 INR
EPS
67,13 INR
Shares outstanding
16,54 млн
No. of employees
1 миң
News stories
From web sources and news partners
Profile
RPG Life Sciences is an Indian pharmaceutical company. Formerly known as Searle Ltd, RPG Life Sciences is part of RPG Enterprises. It has its corporate office in RPG House in Worli, Mumbai. Its three major activities are the manufacturing and marketing of bulk drugs, also known as active pharmaceutical ingredients; pharmaceutical formulation; and fermentation and biotechnology. RPGLS is present in the domestic as well as the international market. It exports its products primarily to Europe, Latin America, Australia and South East Asian countries. Wikipedia
About RPG Life Sciences Ltd
CEO-
Employees1,37 миң
Founded1993
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Last report
2026-ж., 30-окт.
Fiscal period
Q2 2027
- / -
Revenue / Est. (INR)
2,12 млд / -
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
1,80 млд
1,77 млд
1,96 млд
2,12 млд
Cost of goods sold
649,00 млн
661,00 млн
681,50 млн
721,40 млн
Cost of revenue
649,00 млн
661,00 млн
681,50 млн
721,40 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
353,20 млн
570,90 млн
377,60 млн
440,90 млн
Operating expense
807,50 млн
835,00 млн
901,50 млн
1,06 млд
Total operating expenses
1,46 млд
1,50 млд
1,58 млд
1,78 млд
Operating income
343,80 млн
273,30 млн
373,90 млн
336,20 млн
Other non operating income
34,10 млн
-101,90 млн
47,00 млн
42,60 млн
EBT including unusual items
291,20 млн
402,00 млн
414,60 млн
370,40 млн
EBT excluding unusual items
375,40 млн
277,30 млн
414,60 млн
370,40 млн
Income tax expense
69,90 млн
103,00 млн
107,00 млн
88,20 млн
Effective tax rate
24,00%
25,62%
25,81%
23,81%
Other operating expenses
400,50 млн
206,70 млн
464,90 млн
549,90 млн
Net income
221,30 млн
299,00 млн
307,60 млн
266,00 млн
Net profit margin
12,29%
16,90%
15,72%
12,57%
Earnings per share
-
-
-
-
Interest and investment income
-
96,70 млн
-
-
Interest expense
-2,50 млн
-3,90 млн
-6,30 млн
-8,40 млн
Net interest expenses
-2,50 млн
92,80 млн
-6,30 млн
-8,40 млн
Depreciation and amortization charges
53,80 млн
57,40 млн
59,00 млн
68,00 млн
EBITDA
395,75 млн
325,80 млн
426,40 млн
399,70 млн
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору